OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Samidorphan/olanzapine combination therapy for schizophrenia: Efficacy, tolerance and adverse outcomes of regimen, evidence-based review of clinical trials
Syeda Tayyaba Rehan, Abdul Hannan Siddiqui, Zayeema Khan, et al.
Annals of Medicine and Surgery (2022) Vol. 79
Open Access | Times Cited: 9
Syeda Tayyaba Rehan, Abdul Hannan Siddiqui, Zayeema Khan, et al.
Annals of Medicine and Surgery (2022) Vol. 79
Open Access | Times Cited: 9
Showing 9 citing articles:
Antipsychotic-Induced Weight Gain in Severe Mental Illness: Risk Factors and Special Considerations
Nicolette Stogios, Bailey Humber, Sri Mahavir Agarwal, et al.
Current Psychiatry Reports (2023) Vol. 25, Iss. 11, pp. 707-721
Closed Access | Times Cited: 35
Nicolette Stogios, Bailey Humber, Sri Mahavir Agarwal, et al.
Current Psychiatry Reports (2023) Vol. 25, Iss. 11, pp. 707-721
Closed Access | Times Cited: 35
Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia
Mishal Qubad, Robert A. Bittner
Therapeutic Advances in Psychopharmacology (2023) Vol. 13
Open Access | Times Cited: 18
Mishal Qubad, Robert A. Bittner
Therapeutic Advances in Psychopharmacology (2023) Vol. 13
Open Access | Times Cited: 18
A pharmacovigilance study of olanzapine/samidorphan based on FDA Adverse Event Reporting System (FAERS)
Luyao He, Mengting Shen, Lei Zhang, et al.
BMC Pharmacology and Toxicology (2025) Vol. 26, Iss. 1
Open Access
Luyao He, Mengting Shen, Lei Zhang, et al.
BMC Pharmacology and Toxicology (2025) Vol. 26, Iss. 1
Open Access
IUPHAR Themed Review: The Gut Microbiome in Schizophrenia
Srinivas Kamath, Elysia Sokolenko, Kate Collins, et al.
Pharmacological Research (2024), pp. 107561-107561
Open Access | Times Cited: 2
Srinivas Kamath, Elysia Sokolenko, Kate Collins, et al.
Pharmacological Research (2024), pp. 107561-107561
Open Access | Times Cited: 2
Effects of Combined Therapy of Olanzapine and Samidorphan on Safety and Metabolic Parameters in Schizophrenia Patients: A Meta-Analysis
Zhenlei Peng, Qiyu Jia, Junxiong Mao, et al.
Neuropsychiatric Disease and Treatment (2023) Vol. Volume 19, pp. 2295-2308
Open Access | Times Cited: 4
Zhenlei Peng, Qiyu Jia, Junxiong Mao, et al.
Neuropsychiatric Disease and Treatment (2023) Vol. Volume 19, pp. 2295-2308
Open Access | Times Cited: 4
Olanzapine-Samidorphan for Schizophrenia: A Systematic Review and Meta-Analysis
Dhyuti Gupta, Alok Singh
Indian Journal of Psychological Medicine (2023) Vol. 46, Iss. 1, pp. 14-23
Open Access | Times Cited: 2
Dhyuti Gupta, Alok Singh
Indian Journal of Psychological Medicine (2023) Vol. 46, Iss. 1, pp. 14-23
Open Access | Times Cited: 2
Multitarget-Directed Ligands Hitting Serotonin Receptors: A Medicinal Chemistry Survey
Imane Ghafir El Idrissi, A. Di Santo, Enza Lacivita, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 9, pp. 1238-1238
Open Access
Imane Ghafir El Idrissi, A. Di Santo, Enza Lacivita, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 9, pp. 1238-1238
Open Access
Acute Metabolic Shifts: Unraveling the Immediate Impacts of Olanzapine on Glucose Metabolism and Glucagon Signaling in Mice
Tushmitha Sundaralingam, Greg C. Smith, Margaret J. Morris, et al.
(2023)
Closed Access
Tushmitha Sundaralingam, Greg C. Smith, Margaret J. Morris, et al.
(2023)
Closed Access
SECOND TO NONE – RATIONALE, TIMING, AND CLINICAL MANAGEMENT OF CLOZAPINE USE IN SCHIZOPHRENIA
Mishal Qubad, Robert A. Bittner
(2022)
Open Access
Mishal Qubad, Robert A. Bittner
(2022)
Open Access
